See more : Gold Basin Resources Corporation (GXXFF) Income Statement Analysis – Financial Results
Complete financial analysis of SQZ Biotechnologies Company (SQZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SQZ Biotechnologies Company, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- OneLink Corporation (OLNK) Income Statement Analysis – Financial Results
- Shih Wei Navigation Co., Ltd. (5608.TW) Income Statement Analysis – Financial Results
- AFC Ajax NV (0DI7.L) Income Statement Analysis – Financial Results
- 3D Oil Limited (TDO.AX) Income Statement Analysis – Financial Results
- Phoenix Biotech Acquisition Corp. (PBAX) Income Statement Analysis – Financial Results
SQZ Biotechnologies Company (SQZ)
About SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 21.03M | 27.10M | 21.00M | 19.32M | 12.67M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 21.03M | 27.10M | 21.00M | 19.32M | 12.67M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 70.98M | 70.15M | 51.55M | 36.10M | 24.38M |
| General & Administrative | 26.32M | 25.72M | 20.51M | 18.27M | 8.69M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.32M | 25.72M | 20.51M | 18.27M | 8.69M |
| Other Expenses | -449.00K | -8.00K | -13.00K | -791.00K | -1.13M |
| Operating Expenses | 96.85M | 95.87M | 72.06M | 53.58M | 31.94M |
| Cost & Expenses | 96.85M | 95.87M | 72.06M | 53.58M | 33.07M |
| Interest Income | 1.22M | 36.00K | 550.00K | 2.07M | 978.00K |
| Interest Expense | 9.72M | 0.00 | 0.00 | 0.00 | 59.00K |
| Depreciation & Amortization | 21.40M | 11.03M | 10.94M | 6.42M | 1.07M |
| EBITDA | -59.28M | -57.74M | -40.12M | -27.85M | -18.12M |
| EBITDA Ratio | -281.91% | -213.07% | -191.04% | -144.15% | -143.06% |
| Operating Income | -80.68M | -68.77M | -51.06M | -34.27M | -20.40M |
| Operating Income Ratio | -383.68% | -253.78% | -243.16% | -177.37% | -161.05% |
| Total Other Income/Expenses | 1.22M | 28.00K | 537.00K | 2.06M | 1.15M |
| Income Before Tax | -79.46M | -68.74M | -50.52M | -32.20M | -19.25M |
| Income Before Tax Ratio | -377.88% | -253.68% | -240.60% | -166.69% | -151.95% |
| Income Tax Expense | -1.22M | -36.00K | -550.00K | -7.00K | 1.21M |
| Net Income | -78.24M | -68.71M | -49.97M | -32.20M | -19.25M |
| Net Income Ratio | -372.08% | -253.54% | -237.98% | -166.66% | -151.95% |
| EPS | -2.72 | -2.49 | -9.25 | -1.80 | -1.34 |
| EPS Diluted | -2.72 | -2.49 | -9.25 | -1.80 | -1.34 |
| Weighted Avg Shares Out | 28.81M | 27.58M | 5.40M | 17.92M | 14.41M |
| Weighted Avg Shares Out (Dil) | 28.81M | 27.58M | 5.40M | 17.92M | 14.41M |
SQZ Biotechnologies' Cell Therapy Shows Favorable Safety Profile In HPV+ Solid Tumors
SQZ Biotechnologies Company (NYSE: SQZ) announced interim results from the highest-dose monotherapy cohort of Phase 1/2 trial of SQZ-PBMC-HPV in Human Papillomavirus positive (HPV16+) solid tumors. The investigational cell therapy is being evaluated in certain patients with advanced or metastatic HPV16+ cancers.
SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced interim results from the highest-dose monotherapy cohort of its ongoing Phase 1/2 clinical trial of SQZ-PBMC-HPV, an investigational cell therapy...
SQZ Biotechnologies to Present at the 4th Annual Evercore ISI HealthCONx Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the 4th Annual Evercore ISI HealthCONx Conference on December 1st. Armon Sharei, Ph.D.,...
SQZ Biotechnologies to Present at the Stifel 2021 Virtual Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the Stifel 2021 Virtual Healthcare Conference on November 17. Armon Sharei, Ph.D., Chief Executive...
SQZ Biotechnologies to Present New Data at the Society for Immunotherapy of Cancer Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present updates across three oncology programs at various stages of development. The data will be presented...
SQZ Biotechnologies to Present at the Chardan 5th Annual Genetic Medicines Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the Chardan 5th Annual Genetic Medicines Conference on October 4. Armon Sharei, Ph.D.,...
SQZ Biotechnologies to Present at Cantor Global Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the Cantor Global Healthcare Conference on September 29. Armon Sharei, Ph.D., Chief Executive...
SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the first clinical translation of the company's Tolerizing Antigen Carrier (TAC) platform in autoimmune diseases will be for...
SQZ Biotechnologies to Present at Upcoming Health Care Conferences
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at Citi's 16th Annual Virtual Biopharma Conference on September 10, and at the H....
SQZ Biotechnologies Reports Second Quarter 2021 Financial Results and Recent Portfolio Updates
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported second quarter 2021 financial results and recent portfolio updates. “This was an exciting quarter for the company as we...
Source: https://incomestatements.info
Category: Stock Reports